Creative Medical Technology Holdings (CELZ) Accounts Payables (2011 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Accounts Payables of $293455.0 for Q1 2026, up 7.81% year-over-year from $272193.0 in Q1 2025, and up 8.41% quarter-over-quarter from $270686.0 in Q4 2025.
Creative Medical Technology Holdings (CELZ) Accounts Payables (2011 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Accounts Payables for 16 consecutive years, with $293455.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 7.81% year-over-year to $293455.0; the TTM figure through Mar 2026 stood at $293455.0 (up 7.81% YoY), while the FY2025 annual figure was $270686.0, down 1.04% from the prior year.
- Accounts Payables rose to $293455.0 in Q1 2026 per CELZ's latest filing, from $270686.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $3.3 million in Q4 2022 and bottomed at $247159.0 in Q3 2025.
- Historically, Accounts Payables has averaged $481010.2 across 5 years, with a median of $317280.0 in 2023.
- Annual changes were most pronounced in 2022 — Accounts Payables soared 328.89% — and 2023, when it sank 90.29%.
- Creative Medical Technology Holdings' Accounts Payables stood at $3.3 million in 2022, then tumbled by 90.29% to $317280.0 in 2023, then fell by 13.79% to $273530.0 in 2024, then slipped by 1.04% to $270686.0 in 2025, then advanced by 8.41% to $293455.0 in 2026.
- Business Quant data shows CELZ's Accounts Payables at $293455.0 in Q1 2026, $270686.0 in Q4 2025, and $247159.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.77 Bn | 131.91 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.17 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 59.60 Bn | 54.47 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 35.57 Mn |
| 10 | Creative Medical Technology Holdings | 1.80 Mn | 1.80 Mn | - | 684,401.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 684,401.00 |
| Mar 31, 2026 | 293,455.00 |
| Dec 31, 2025 | 270,686.00 |
| Sep 30, 2025 | 247,159.00 |
| Jun 30, 2025 | 263,450.00 |
| Mar 31, 2025 | 272,193.00 |
| Dec 31, 2024 | 273,530.00 |
| Sep 30, 2024 | 273,794.00 |
| Jun 30, 2024 | 322,158.00 |
| Mar 31, 2024 | 336,845.00 |
| Dec 31, 2023 | 317,280.00 |
| Sep 30, 2023 | 367,045.00 |
| Jun 30, 2023 | 344,413.00 |
| Mar 31, 2023 | 353,422.00 |
| Dec 31, 2022 | 3.27 Mn |
| Sep 30, 2022 | 327,843.00 |
| Jun 30, 2022 | 310,681.00 |
| Mar 31, 2022 | 335,681.00 |
| Dec 31, 2021 | 761,862.00 |
| Sep 30, 2021 | 454,525.00 |